Skip to main
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 18 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insmed is expected to see strong profit growth in the next five years, driven by the potential success of its new bronchiectasis drug Brinsupri and expansion into other respiratory diseases. The company's focus on sustainability and patient needs has also garnered positive feedback from physicians, indicating potential for continued success in the future. The company's higher than expected revenue and well-positioned for short-term and long-term growth support a positive outlook on the stock.

Bears say

Insmed is a biopharmaceutical company that is currently experiencing strong initial launch signals for its marketed drugs and has a diverse pipeline with potential for expansion into new indications. However, the company faces potential risks related to sustainability and regulatory approval for new indications. Despite current positive market conditions, the stock's long-term outlook may be negatively impacted by these risks, leading to potential underperformance compared to expectations.

Insmed (INSM) has been analyzed by 18 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Strong Buy based on their latest research and market trends.

According to 18 analysts, Insmed (INSM) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $209.72, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $209.72, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.